162 related articles for article (PubMed ID: 21939268)
1. Chemical and enzymatic reductive activation of acylfulvene to isomeric cytotoxic reactive intermediates.
Pietsch KE; Neels JF; Yu X; Gong J; Sturla SJ
Chem Res Toxicol; 2011 Nov; 24(11):2044-54. PubMed ID: 21939268
[TBL] [Abstract][Full Text] [Related]
2. Quantification of acylfulvene- and illudin S-DNA adducts in cells with variable bioactivation capacities.
Pietsch KE; van Midwoud PM; Villalta PW; Sturla SJ
Chem Res Toxicol; 2013 Jan; 26(1):146-55. PubMed ID: 23227857
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenes.
Liu X; Pietsch KE; Sturla SJ
Chem Res Toxicol; 2011 May; 24(5):726-36. PubMed ID: 21443269
[TBL] [Abstract][Full Text] [Related]
4. Depurinating acylfulvene-DNA adducts: characterizing cellular chemical reactions of a selective antitumor agent.
Gong J; Vaidyanathan VG; Yu X; Kensler TW; Peterson LA; Sturla SJ
J Am Chem Soc; 2007 Feb; 129(7):2101-11. PubMed ID: 17256933
[TBL] [Abstract][Full Text] [Related]
5. Profiling patterns of glutathione reductase inhibition by the natural product illudin S and its acylfulvene analogues.
Liu X; Sturla SJ
Mol Biosyst; 2009 Sep; 5(9):1013-24. PubMed ID: 19668867
[TBL] [Abstract][Full Text] [Related]
6. Investigating the role of stereochemistry in the activity of anticancer acylfulvenes: synthesis, reductase-mediated bioactivation, and cellular toxicity.
Gong J; Neels JF; Yu X; Kensler TW; Peterson LA; Sturla SJ
J Med Chem; 2006 Apr; 49(8):2593-9. PubMed ID: 16610802
[TBL] [Abstract][Full Text] [Related]
7. Quantitative correlation of drug bioactivation and deoxyadenosine alkylation by acylfulvene.
Neels JF; Gong J; Yu X; Sturla SJ
Chem Res Toxicol; 2007 Oct; 20(10):1513-9. PubMed ID: 17900171
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of antitumor acylfulvene by rat liver cytosol.
McMorris TC; Elayadi AN; Yu J; Kelner MJ
Biochem Pharmacol; 1999 Jan; 57(1):83-8. PubMed ID: 9920288
[TBL] [Abstract][Full Text] [Related]
9. Characterization of acylfulvene histiospecific toxicity in human tumor cell lines.
Kelner MJ; McMorris TC; Montoya MA; Estes L; Uglik SF; Rutherford M; Samson KM; Bagnell RD; Taetle R
Cancer Chemother Pharmacol; 1998; 41(3):237-42. PubMed ID: 9443641
[TBL] [Abstract][Full Text] [Related]
10. Acylfulvenes, a new class of potent antitumor agents.
McMorris TC; Kelner MJ; Wang W; Diaz MA; Estes LA; Taetle R
Experientia; 1996 Jan; 52(1):75-80. PubMed ID: 8575564
[TBL] [Abstract][Full Text] [Related]
11. Sulfotransferase-independent genotoxicity of illudin S and its acylfulvene derivatives in bacterial and mammalian cells.
Glatt H; Pietsch KE; Sturla SJ; Meinl W
Arch Toxicol; 2014 Jan; 88(1):161-9. PubMed ID: 23881331
[TBL] [Abstract][Full Text] [Related]
12. A Chemical Proteomic Analysis of Illudin-Interacting Proteins.
Le P; Nodwell MB; Eirich J; Sieber SA
Chemistry; 2019 Sep; 25(54):12644-12651. PubMed ID: 31310394
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent.
Yu X; Erzinger MM; Pietsch KE; Cervoni-Curet FN; Whang J; Niederhuber J; Sturla SJ
J Pharmacol Exp Ther; 2012 Nov; 343(2):426-33. PubMed ID: 22895897
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of antitumor hydroxymethylacylfulvene by rat liver cytosol.
McMorris TC; Elayadi AN; Yu J; Hu Y; Kelner MJ
Drug Metab Dispos; 1999 Sep; 27(9):983-5. PubMed ID: 10460795
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship studies of illudins: analogues possessing a spiro-cyclobutane ring.
McMorris TC; Cong Q; Kelner MJ
J Org Chem; 2003 Dec; 68(25):9648-53. PubMed ID: 14656090
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of RNA polymerase II stalling by DNA alkylation.
Malvezzi S; Farnung L; Aloisi CMN; Angelov T; Cramer P; Sturla SJ
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12172-12177. PubMed ID: 29087308
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Cytotoxicity by Transcription-Coupled Nucleotide Excision Repair Is Independent of the Requirement for Bioactivation of Acylfulvene.
Otto C; Spivak G; Aloisi CM; Menigatti M; Naegeli H; Hanawalt PC; Tanasova M; Sturla SJ
Chem Res Toxicol; 2017 Mar; 30(3):769-776. PubMed ID: 28076683
[TBL] [Abstract][Full Text] [Related]
18. Chemistry and biology of acylfulvenes: sesquiterpene-derived antitumor agents.
Tanasova M; Sturla SJ
Chem Rev; 2012 Jun; 112(6):3578-610. PubMed ID: 22482429
[No Abstract] [Full Text] [Related]
19. Improved efficacy of acylfulvene in colon cancer cells when combined with a nuclear excision repair inhibitor.
van Midwoud PM; Sturla SJ
Chem Res Toxicol; 2013 Nov; 26(11):1674-82. PubMed ID: 24099590
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity studies of urea, carbamate, and sulfonamide derivatives of acylfulvene.
McMorris TC; Chimmani R; Alisala K; Staake MD; Banda G; Kelner MJ
J Med Chem; 2010 Feb; 53(3):1109-16. PubMed ID: 20067264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
